Molecular Tumor Boards seek to recommend therapeutics to patients based on varying levels of evidence linking specific genetic alterations to treatment response. This commentary highlights the study by Kato and colleagues, which reports the usage of precision medicine approaches in rare and ultra‐rare tumor subtypes, as well as the need to discover effective drugs for tumor subtypes without known targetable genetic alterations.